These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30045610)

  • 21. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
    Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R; Yarman S; Bayraktaroglu T; Boztepe H; Alagöl F
    Clin Drug Investig; 2007; 27(6):419-33. PubMed ID: 17506592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between bone mineral density and the frequent administration of epidural steroid injections in postmenopausal women with low back pain.
    Kim S; Hwang B
    Pain Res Manag; 2014; 19(1):30-4. PubMed ID: 24404559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone turnover markers in postmenopausal osteoporosis and their correlation with bone mineral density and menopause duration.
    Gurban CV; Balaş MO; Vlad MM; Caraba AE; Jianu AM; Bernad ES; Borza C; Bănicioiu-Covei S; Motoc AGM
    Rom J Morphol Embryol; 2019; 60(4):1127-1135. PubMed ID: 32239087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of low bone mass in postmenopausal Kuwaiti women residents in the largest province of Kuwait.
    Al-Shoumer KA; Nair V
    Arch Osteoporos; 2012; 7():147-53. PubMed ID: 23225292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
    Hejdova M; Palicka V; Kucera Z; Vlcek J
    Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.